ABBV

AbbVie ABBV is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued strength of the company’s blockbuster immunology franchise, the performance of its neuroscience portfolio is also expected to be closely watched. In the first quarter, neuroscience revenues rose 26% year over year to nearly $2.88 billion, reflecting broad-based momentum across its key brands. The Zacks Consensus Estimate for second-quarter 2026 neuroscience revenues is pegged at $3.09 billion, indicating 15% year-over-year growth. Higher sales of Botox Therapeutic and depression drug Vraylar are likely to have contributed to growth during the quarter. Sales of the oral migraine drugs Ubrelvy and Qulipta likely benefited from continued market share gains across their approved indications. Vyalev is also expected to be a key contributor to the neuroscience franchise, having demonstrated strong commercial momentum since its U.S. launch last year. After generating $201 million from the drug’s sales in first-quarter 2026, the Zacks Consensus Estimate projects second-quarter sales of $238 million. Management had previously reiterated that Vyalev is on track to achieve blockbuster status this year. Another quarter of strong uptake would further strengthen the drug's position as an important long-term growth driver for AbbVie's neuroscience business. AbbVie faces competition from large-cap biotech/pharmaceutical companies in the market, which include Biogen BIIB and Johnson & Johnson JNJ. As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for Alzheimer's disease. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression. J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression. Shares of AbbVie have underperformed the industry year to date, as shown in the chart below. Image Source: Zacks Investment Research...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.84 per share. This compares to earnings of $2.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2.11%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.67 per share when it actually produced earnings of $2.7, delivering a surprise of +1.12%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Johnson & Johnson, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $25.31 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.53%. This compares to year-ago revenues of $23.74 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Johnson & Johnson shares have added about 22.7% since the beginning of the year versus the S&P 500's gain of 10.2%. While Johnson & Johnson has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Johnson & Johnson was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. Y...

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growt

This article first appeared on GuruFocus. HSBC identified 10 Buy-rated stocks it believes are well positioned ahead of the second-quarter earnings season, citing favorable trends across technology, financial, consumer and industrial sectors. HSBC named Amazon (NASDAQ:AMZN), Microsoft (MSFT), Meta Platforms (NASDAQ:META), Alphabet (GOOGL), AbbVie (ABBV), Caterpillar (CAT), Marriott International (MAR), Vertiv (VRT), NextPower (NXT) and Wells Fargo (WFC) as its preferred earnings-season ideas. The firm said the selections reflect company-specific growth drivers rather than a single sector theme. Warning! GuruFocus has detected 5 Warning Sign with AMZN. Is AMZN fairly valued? Test your thesis with our free DCF calculator. HSBC expects Amazon to benefit from continued cloud computing demand and AI infrastructure investments, while Microsoft could see further momentum from Azure AI services. The brokerage also pointed to Meta's AI-powered advertising tools, Alphabet's cloud and search businesses, and Vertiv's exposure to expanding data center spending. Outside technology, HSBC said AbbVie's immunology portfolio, Caterpillar's exposure to AI-related power demand, Marriott's asset-light business model and Wells Fargo's improving earnings outlook could support results. The brokerage also highlighted NextPower's project backlog and expansion efforts as potential growth catalysts heading into the reporting season.

AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Marke

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $450.1 billion, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care. The drug giant is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Friday, Jul. 31. Ahead of the event, analysts expect ABBV to report a profit of $3.79 per share on a diluted basis, up 27.6% from $2.97 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Nasdaq Futures Plunge as Samsung Sparks Chip Selloff AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years The Nasdaq-100 Could Be Forming a Textbook Diamond Top. Here's What to Watch on the QQQ Chart Now. Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect ABBV to report EPS of $14.28, up 42.8% from $10 in fiscal 2025. Its EPS is expected to rise 12.3% year over year to $16.03 in fiscal 2027. ABBV stock has outperformed the S&P 500 Index’s ($SPX) 20.5% gains over the past 52 weeks, with shares up 35.7% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 22.4% returns over the same time frame. ABBV rallied on strong execution in immunology and neuroscience. Skyrizi and Rinvoq posted double-digit growth and continue to offset Humira, while neuroscience revenue rose about 24% on strength in migraine and psychiatry. Moreover, management highlighted Skyrizi’s efficacy advantage and new pipeline additions, including the $10.9 billion Apogee Enterprises, Inc. (APOG) deal, as key to future growth. AbbVie also committed $1.4 billion to U.S. manufacturing and raised EPS guidance. While investing at record levels, the company maintains its dividend focus and sees long-term momentum despite competition and macro uncertainty. Analysts’ consensus opinion on ABBV stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 31 analysts covering the stock, 20 advise a “Strong Buy” rating, two suggest a “Moderate Buy” and nine give a “Hold.” ABBV’s average analyst price targe...

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

AbbVie ABBV remains a dominant force in the immunology segment, from where it generates nearly half of its top line. This growth is mainly driven by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq, which have helped the company return to top-line growth despite the U.S. loss of exclusivity for its legacy drug, Humira, in 2023. Investors’ focus will primarily be on the sales performance of these two drugs when AbbVie reports its second-quarter 2026 results on July 31. The Zacks Consensus Estimate for Skyrizi sales is pegged at $5.49 billion, while the same for Rinvoq stands at $2.47 billion. Continued momentum from these therapies, supported by market share gains, is expected to drive immunology sales in the quarter. Meanwhile, Humira sales are expected to continue their downward trajectory, with the Zacks Consensus Estimate pegged at $744 million for the quarter. AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, as well as a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD). The company has also been expanding its presence beyond immunology into oncology and neuroscience. In recent years, ABBV has added Elahere, Emrelis and, most recently, Decnupaz, bringing its total number of oncology therapies to six. Growth in its neuroscience segment has also been supported by the increasing uptake of its migraine drugs, Ubrelvy and Qulipta, as well as the Parkinson’s disease drug Vyalev. The immunology market is highly competitive. A key player in this area is Johnson & Johnson JNJ, which already markets two blockbuster drugs — Stelara and Tremfya. These medications are approved across multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya. It recently secured approval for a new immunology drug, Icotyde, to treat moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi. Another pharma giant expanding its presence in immunology is Eli Lilly LLY, following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology dr...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth. The 11 therapeutics stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 14.5%. Luckily, therapeutics stocks have performed well with share prices up 18.9% on average since the latest earnings results. Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions. AbbVie reported revenues of $15 billion, up 12.4% year on year. This print exceeded analysts’ expectations by 1.7%. Despite the top-line beat, it was still a mixed quarter for the company. "We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie's key growth drivers continue to deliver strong performance and support our enhanced full-year outlook," said Robert A. Michael, chairman and chief executive officer, AbbVie. Interestingly, the stock is up 31.6% since reporting and currently trades at $260.14. Is now the time to buy AbbVie? Access our full analysis of the earnings results here, it’s free. Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases. Moderna reported revenues of $389 million, up 260% year on year, outperforming analysts’ expectations by 55.8%. The business had an incredible quarter with a beat of analysts’ EPS estimates. Moderna pulled off the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 75.2% since reporting. It curre...

Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) EPCORE DLBCL-4 demonstrated improved PFS with a chemotherapy-free combination treatment regimen in patients with R/R DLBCL NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab plus gemcitabine plus oxaliplatin (R-GemOx) in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy. Based on topline results from the prespecified primary analysis, the trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40 [95% CI 0.30, 0.55]; p-value <0.0001) and 56% (HR 0.44 [95% CI 0.33, 0.60]; p-value <0.0001), based on different censoring rules in the U.S. and outside the U.S., respectively. The safety profile of epcoritamab when administered in combination with lenalidomide was consistent with the known safety profiles of the individual agents (epcoritamab and lenalidomide). "Despite recent advances, there remains a critical need for innovative therapies to improve outcomes for those battling DLBCL, an aggressive and often difficult-to-treat cancer," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "Today's encouraging topline results highlight the potential of epcoritamab, a fixed-treatment therapy, in combination with lenalidomide, as a meaningful treatment option after initial disease progression." AbbVie and Genmab will engage global regulatory authorities to discuss next steps. Data will be submitted for presentation at a future medical meeting. About the EPCORE® DLBCL-4 Trial EPCORE DLBCL-4 (NCT06508658) is a global Phase 3 open label, multi-center, randomized trial to evaluate the efficacy of epcoritamab (GEN3013, DuoBody®-CD3xCD20) in combination with lenalidomide co...

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-second-quarter-2026-earnings-conference-call-302810896.html

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic leukemia in less-fit patients. The company also received U.S. FDA approval for SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. AbbVie operates at the intersection of large-scale pharmaceuticals and medical aesthetics, with products that span immunology, oncology, neuroscience and cosmetic treatments. The latest data in chronic lymphocytic leukemia represents another clinical milestone in its blood cancer portfolio. At the same time, SKINVIVE by JUVÉDERM extends its aesthetics reach into a new treatment area. For investors, these updates contribute to a broader picture of a company with exposure to both therapeutic and elective procedure trends. Readers may want to track how quickly clinicians adopt the new venetoclax combination and how SKINVIVE is received by dermatologists and patients focused on neck rejuvenation. Uptake, pricing decisions and any additional regulatory or reimbursement developments could influence how meaningful these launches become within AbbVie’s overall mix. Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie. 2 things going right for AbbVie that this headline doesn't cover. For AbbVie, this news showcases how its two main engines, oncology and aesthetics, can move in tandem. The CLL14 data reinforces the role of venetoclax plus obinutuzumab as a fixed-duration option in untreated chronic lymphocytic leukemia for less-fit patients, which can matter in a field where patients and physicians weigh long-term toxicity and treatment fatigue. A longer progression-free survival and a median 7.6-year time to next treatment, alongside a known safety profile, helps AbbVie compete with large hematology players such as Johnson & Johnson and Roche. On the aesthetics side, SKINVIVE by JUVÉDERM adds a first-to-market hyaluronic acid injectable for neck lines, extending AbbVie’s reach beyond facial indications where it already competes with Merz and Galderma. Required provider training and a minimally invasive procedure with six-month durability may support phys...